Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model

Cytokine

Volumn 68, Issue 2, 2014, Pages 76-85

  Ahmad, Sheikh Fayaz ^a   Zoheir, Khairy M A ^a,b   Bakheet, Saleh A ^a   Ashour, Abdelkader E ^a   Attia, Sabry M ^a,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Al Azhar University   (Egypt)

Author keywords

5 Aminoisoquinolinone; Adjuvant induced arthritis; Inflammatory mediators; PARP 1 inhibitor; Regulatory T cells

Indexed keywords

5 AMINOISOQUINOLINONE; ANTIRHEUMATIC AGENT; I KAPPA B KINASE ALPHA; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; 5-AMINOISOQUINOLINONE; AUTACOID; CD4 ANTIGEN; ENZYME INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; I KAPPA B; INTERLEUKIN 2 RECEPTOR ALPHA; ISOQUINOLINE DERIVATIVE; NF-KAPPAB INHIBITOR ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TNFRSF18 PROTEIN, MOUSE;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GATA 3 GENE; GENE EXPRESSION; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; EDEMA; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD4; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EDEMA; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOQUINOLINES; LYMPHOCYTE COUNT; MICE, INBRED BALB C; POLY(ADP-RIBOSE) POLYMERASES; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION FACTOR RELA;

EID: 84899880360     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.04.006     Document Type: Article

References (63)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
2. Banerjee S., Webber C., Poole A.R. The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. Cell Immunol 1992, 144:347-357.
3. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
4. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
5. Mason U., Aldrich J., Breedveld F., Davis C.B., Elliott M., et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 2002, 29:220-229.
6. Graca L., Waldmann H. Reprogramming the immune system using antibodies. Methods Mol Biol 2006, 333:247-268.
7. Nguyen L.T., Jacobs J., Mathis D., Benoist C. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum 2007, 56:509-520.
8. Boissier M.C., Assier E., Biton J., Denys A., Falgarone G., Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009, 76:10-14.
9. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
10. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
11. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29-37.
12. Beinke S., Ley S.C. Functions of NF-kappaB1 and NFkappaB2 in immune cell biology. Biochem J 2004, 382:393-409.
13. D'Amours D., Desnoyers S., D'Silva I., Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342(Pt 2):249-268.
14. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54:375-429.
15. Szabo C. Poly(ADP-ribose) polymerase activation by reactive nitrogen species-relevance for the pathogenesis of inflammation. Nitric Oxide 2006, 14:169-179.
16. Di Paola R., Mazzon E., Muià C., Terrana D., Greco S., Britti D., et al. 5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats. J Clin Periodontol 2007, 34(2):95-102.
17. Gonzalez-Rey E., Martínez-Romero R., O'Valle F., Aguilar-Quesada R., Conde C., Delgado M., et al. Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. PLoS One 2007, 2(10):e1071. 31.
18. Szabo G., Bährle S., Stumpf N. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002, 90:100-106.
19. Cuzzocrea S., Mazzon E., Di Paola R., Genovese T., Patel N.S., Muià C., et al. 5-Aminoisoquinolinone reduces colon injury by experimental colitis. Naunyn Schmiedebergs Arch Pharmacol 2004, 370(6):464-473.
20. Nicolescu A.C., Holt A., Kandasamy A.D., Pacher P., Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun 2009, 387(4):646-650. 2.
21. Ahmad S.F., Khan B., Bani S., Suri K.A., Satti N.K., Qazi G.N. Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol Res 2006, 53:233-240.
22. Jagdish N.S., Awatef M., Zaini M.A. Comparison between plethysmometer and micrometer methods to measure acute paw oedema for screening anti-inflammatory activity in mice. Inflammopharmacology 2004, 12(1):89-94.
23. Ahmad S.F., Zoheir K.M., Abdel-Hamied H.E., Ashour A.E., Bakheet S.A., Attia S.M., et al. Grape seed proanthocyanidin extract has potent anti-arthritic effects on collagen-induced arthritis by modifying the T cell balance. Int Immunopharmacol 2013, 17(1):79-87.
24. Wan Y.Y., Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007, 445:766-770.
25. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G.G., Chou Y.K., et al. Decreased Foxp3 levels in multiple sclerosis patients. J Neurosci Res 2005, 81:45-52.
26. Balandina A., Lécart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune Myasthenia gravis. Blood 2005, 105:735-741.
27. Lubberts E., Koenders M.I., Oppers-Walgreen B., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
28. Reuter S., Prasad S., Phromnoi K., Kannappan R., Yadav V.R., Aggarwal B.B. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-kB ligand and tumor cells in vitro through inhibition of the NF-kB cell signaling pathway. Mol Cancer Res 2010, 8(10):1425-1436.
29. Kim H.S., Kim A.R., Park H.J., Park D.K., Kim do K., Ko N.Y., et al. Morus bombycis Koidzumi extract suppresses collagen-induced arthritis by inhibiting the activation of nuclear factor-kB and activator protein-1 in mice. J Ethnopharmacol 2011, 136(3):392-398. 14.
30. Hakme A., Wong H.K., Dantzer F., Schreiber V. The expanding field of poly(ADPribosyl) ation reactions. EMBO Rep 2008, 9:1094-1100.
31. Kraus W.L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol 2008, 20:294-302.
32. Beneke S. Poly(ADP-ribose) polymerase activity in different pathologies the link to inflammation and infarction. Exp Gerontol 2008, 43:605-614.
33. Esposito E., Cuzzocrea S. Superoxide, NO, peroxynitrite and PARP in circulatory shock and inflammation. Front Biosci (Landmark Ed) 2009, 14:263-296.
34. Genovese T., Mazzon E., Muia C., Patel N.S., Threadgill M.D., Bramanti P., et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 2005, 312:449-457.
35. Hendryk S., Czuba Z.P., Jedrzejowska-Szypulka H., Szliszka E., Phillips V.A., Threadgill M.D., et al. Influence of 5-aminoisoquinolin-1-one (5-AIQ) on neutrophil chemiluminescence in rats with transient and prolonged focal cerebral ischemia and after reperfusion. J Physiol Pharmacol 2008, 59:811-822.
36. Pacher P., Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 2007, 25:235-260.
37. Szabo C., Lim L.H., Cuzzocrea S., Getting S.J., Zingarelli B., Flower R.J., et al. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts anti-inflammatory effects. J Exp Med 1997, 186:1041-1049.
38. Karin M., Delhase M. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?. PNAS, Proc Natl Acad Sci USA 1998, 95:9067-9069.
39. Huang D., Yang C.Z., Yao L., Wang Y., Liao Y.H., Huang K. Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina. Arch Med Res 2008, 39:775-784.
40. Naura A.S., Datta R., Hans C.P., Zerfaoui M., Rezk B.M., Errami Y., et al. Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J 2009, 33:252-262.
41. Goronzy J.J., Weyand C.M. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol 2001, 22:251-255.
42. Falgarone G., Semerano L., Rullé S., Boissier M.C. Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine 2009, 76(4):327-332.
43. Nistala K., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010, 107(33):14751-14756.
44. Ferenczi K., Burack L., Pope M., Krueger J.G., Austin L.M. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000, 14:63-78.
45. Baecher-Allan C., Viglietta V., Hafler D.A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16:89-97.
46. Dombrecht E.J., Aerts N.E., Schuerwegh A.J., Hagendorens M.M., Ebo D.G., Ebo D.G., et al. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:31-37.
47. Cao D., Vollenhoven Rvan, Klareskog L., Trollmo C., Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004, 6:R335-R346.
48. Mekala D.J., Geiger T.L. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 2005, 105(5):2090-2092.
49. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
50. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
51. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004, 200:277-285.
52. van den Berg W.B., Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:549-553.
53. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2(52):52ra72. 6.
54. Patel M., Xu D., Kewin P., Choo-Kang B., McSharry C., Thomson N.C., et al. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen induced arthritis. Eur J Immunol 2005, 35:3581-3590.
55. Ghosh S., Hayden M.S. New regulators of NF-κB in inflammation. Nat Rev Immunol 2008, 8(11):837-848.
56. Simmonds R.E., Foxwell B.M. Signalling, inflammation and arthritis: NFkappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584-590.
57. Brown K.D., Claudio E., Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008, 10(4):212.
58. Bingham C.O. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol 2002, 65:3-9.
59. Nistala K., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010, 10:14751-14756.
60. Szabo S.J., Sullivan B.M., Stemmann C., Satoskar A.R., Sleckman B.P., Glimcher L.H. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002, 295:338-342.
61. Djuretic I.M., Levanon D., Negreanu V., Groner Y., Rao A., Ansel K.M. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol 2007, 8:145-153.
62. Hwang E.S., Szabo S.J., Schwartzberg P.L., Glimcher L.H. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005, 307:430-433.
63. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.